Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives
2019 ◽
Vol 41
(6)
◽
pp. 1175-1185
◽
2014 ◽
Vol 147
(2)
◽
pp. 443-443
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. e11531-e11531
2016 ◽
Vol 160
(1)
◽
pp. 187-196
◽
2019 ◽
Vol 22
(6)
◽
pp. 584-592
◽